updat forecast estim
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim
price data dec
rate updat dec
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
zoeti clear leader global anim health industri
believ possess widest moat player
industri whole possess mani characterist
conduc moat zoeti global infrastructur give cost
advantag peer firm also fend competit
impress breadth product portfolio
includ number drug specif canin felin ailment
anim health industri larg ignor
busi often buri within larger human health compani
mani attract characterist includ cash-pay
buyer fragment custom base minim gener
competit due fragment cash-pay custom base
anim drugmak hold signific price power human
health side firm tradit merci payer
govern payer larg managed-car organ
power forc gener util squash price increas even
extrem case forc price cut onto drug manufactur
howev anim health product purchas fragment
group protein produc veterinarian pet owner allow
littl bargain power highli concentr anim
industri also benefit favor growth tailwind
allow zoeti increas revenu mid-single-digit
long-term growth rate product anim side rise
standard live emerg market lead wider
adopt meat-heavi diet drive greater demand livestock
product companion side zoeti benefit pet owner
increasingli strong relationship pet member
famili drastic increas willing pay
expens treatment zoeti like grow rate rel
close industri abl maintain
above-averag margin due scale especi emerg
market zoeti scale allow use salesforc
smaller competitor often forc reli expens
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
zoeti sell anti-infect vaccin parasiticid diagnost
health product anim firm earn total revenu
product anim cattl pig poultri companion
anim dog hors cat product make remaind firm
largest market share industri previous anim
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
zoeti report strong third-quart perform held
surpris leav fair valu estim
unchang firm track meet full-year
project although cattl segment display
soft entir livestock divis saw healthi quarterli
oper growth thank double-digit growth
poultri fish typic companion anim
segment grew faster oper third
quarter includ addit abaxi diagnost
busi continu strength firm new product
addit invest manufactur capac
commerci organ underscor zoeti
zoeti abl reap reward invest
novel therapeut specif develop
companion anim market apoquel cytopoint
domin leader dermatolog market
estim share along simparica collect
novel product fuel double-digit growth zoeti
companion anim segment offset declin
older product manag reveal work
new monoclon antibodi pain dog cat
could big opportun arthriti older
companion anim quit common main treatment
option pet current non-steroid anti-
inflammatori may may effect
long term clear mechan action
character new therapi seen human
pharmaceut compani attempt address pain
monoclon antibodi target nerv growth factor
case therapi turn significantli
efficaci nsaid human entir class
drug dog troubl side effect
recent human side effect concern
acceler deterior affect arthrit joint
lead earlier greater incid joint replac
howev clear whether deterior due
actual therapeut agent simpli driven
aggress patient use joint pain reliev
class drug eventu approv human use
expect market potenti could substanti
howev consid number time regul
interven halt clinic trial due emerg
side effect less confid therapi
reach commerci human hand
lower hurdl anim use could work zoeti favor
expect monoclon antibodi pain reach canin
market human market
boost fair valu estim per
share primarili reflect zoeti new tax rate
roughli basi point lower origin
anticip also includ slightli optimist
project improv profit longer term
continu estim low-double-digit annual growth
companion anim segment
project growth earn interest
long term
ration
remain favor profit gain follow
product portfolio
invest brand companion anim drug busi
project adjust oper margin reach
basi point next five year
expect improv split nearli evenli
gain gross margin thank slim
product portfolio product anim consolid
manufactur site half driven
effici deploy sale field support howev
benefit firm effici program
slightli off-set lower-margin emerg market make
grow portion zoeti sale well greater
 invest maintain brand drug innov
whole project factor translat
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
patent allow zoeti charg premium price
insul competit firm strong brand name
anoth advantag competitor custom
use drug potenti million dollar worth
livestock pet love like famili member
will pay premium buy firm trust
zoeti also enjoy anoth intang asset comparison
competitor embed larger human
pharmaceut firm zoeti free develop therapeut
base unmet anim need competitor applic
therapeut origin design human anim
market also mean firm unlik invest
animal-specif therapi sizabl opportun
relat unmet anim need zoeti pioneer
includ cytopoint canin allergi
scale also provid zoeti key advantag
highli fragment custom base salesforc
distribut relationship extrem import
launch new product simpl get one
larg payer managed-car organ medicar
govern board compani need individu
deal veterinarian meat produc zoeti broad
portfolio support salesforc allow firm
bypass distributor
barrier entri signific capit time
although nearli expens time-consum
human health still challeng bring new
anim health product market given small market
size rel modest sale potenti product
reward often justifi new competitor pursu
clinic trial bring product market
one best exampl strength zoeti moat
pain medic dog rimadyl product lost
patent exclus sale current
higher vet relationship trust
adjust averag annual earn growth
base averag volatil cash flow divers
product portfolio anim health market rate
zoeti uncertainti medium
base case forecast long-term tax rate
long-term oper margin firm
abl boost sale product anim product
leverag greater price power companion anim
portfolio project adjust oper margin
fair valu estim would per share firm
lose revenu due greater restrict
antibiot use anim face flat oper margin
penetr emerg market pressur profit
fair valu would fall per share
zoeti enjoy wide econom moat thank intang
asset scale although patent essenti
maintain product anim health industri least
firm revenu come product protect
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
zoeti allow rimadyl maintain increas
believ zoeti stabl moat trend compani
compet matur industri experienc
signific chang heavi concentr among
top firm revolutionari product develop
expect industri face materi chang
competit landscap
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
oimprov standard live emerg market
drive greater adopt meat-heavi diet
longer term
ostrict regul restrict antibiot use
ocompanion anim increasingli view famili
spend pet healthcar
olower-margin emerging-market sale make
increas portion compani sale creat
headwind zoeti margin
osinc anim health industri lack larg payer
like medicar single-pay govern larg
oemerging-market custom may price-
sensit open use gener product
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
zoeti enjoy solid financi flexibl even leverag
tick financ purchas pharmaq
abbott anim health busi long-term debt
billion end zoeti alreadi brought
debt/ebitda time time two
year leverag low end target rang
time manag aim remain
comfort interest coverag around time
base averag volatil cash flow divers
product portfolio anim health market rate
zoeti uncertainti medium thank grow consum
concern use antibiot food suppli
meat product industri final begun react
industri alreadi roll new standard call
voluntari monitor use anim howev
grassroot pressur continu build risk
fda could eventu issu restrict guidelin
product anim segment offer rel
steadi growth remain expos macroeconom trend
emerg market adopt higher-protein diet
like fuel underli demand zoeti product
slower growth china brazil rippl effect could
reach zoeti companion anim market price
elast pet health care clear pet owner continu
spend pet point rise price
may owner will bear
segment market vulner macroeconom
downturn caus consum pull back spend
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
base nearli three year sinc zoeti spun
give firm standard stewardship rate
ceo juan ramon alaix previous ran busi
presid anim health busi firm
separ leadership anim health unit
success integr fort dodg anim health
alpharma acquisit region
presid central/southern europ
pharmaceut divis believ seven year run
compani give signific oper experi
thu far alaix focus increas zoeti scale
breadth seri acquisit allow
firm enter adjac market includ aquacultur
monoclon antibodi pet
abrupt departur former cfo paul herendeen
valeant last spring glenn david step role
david longtim veteran deep experi
healthcar well acquisit integr
new busi expect see dramat
departur firm current strategi serial
acquisit though leverag may settl lower
expect herendeen aggress stanc
repres date owner name posit common share held report holder issuer
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
rise tariff meat leav us cautiou zoeti
livestock segment chang fve oct
hold steadi fair valu estim zoeti
per share make slight adjust
product anim project
product segment tend grow long term along
economi expect could addit
pressur trickl rise tariff attach
meat midterm enough
move needl valuat may make
revis zoeti report third-quart result week
zoeti seen sever quarter robust revenu growth
product anim segment strength swine
poultri thank increas meat product
occur feed price fallen expect see rise
tariff pork china mexico whop
tariff respect could damp demand
farmer slow expans worst begin cull
livestock especi feed price rise zoeti would also
see swine sale come pressur although swine
sale contribut zoeti total revenu
declin set could modestli hurt zoeti perform
midterm
therapeut togeth exampl zoeti pair
heartworm diagnost recent approv
diroban treat heartworm well revolut
recogn acquisit provid zoeti
broader rang product sell companion anim
market there question zoeti sell great deal
product vet howev dont think combin firm
necessarili strike heart idexx competit
advantag primarili focus strong
partnership vet anim hospit yet
see companion anim healthcar compani partner
close vet improv deliveri
medic servic oper well-b anim
hospit relationship abl foster
vet goe far beyond simpli suppli diagnost test
start rang diagnost servic
also branch integr practic manag
softwar consult servic strength
relationship one major reason abl
shift all-direct distribut product includ lab
consum without miss beat zoeti abaxi
yet forg kind collabor vet
zoeti impend acquisit abaxi threat
think acquisit abaxi zoeti make
strateg sens think combin compani
pose larger competit threat narrow-moat idexx lab
market leader benchtop vet analyz hold
steadi fair valu estim zoeti wide-
moat zoeti long indic interest enlarg
presenc anim diagnost think fold abaxi
zoeti therapeut portfolio companion
anim make senseth firm alreadi relationship
vet veterinari distributor tie diagnost
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
equival
net properti plant equip
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
